在3月21~3月22日召开的“2025呼吸健康与气道疾病国际论坛”上，中外指南对于“重度哮喘”的定义、诊断、分型、治疗药物、“临床治愈”等方面的最新推荐以及对应的异同点成为会议讨论焦点。

The FDA has requested five large clinical trials to evaluate fixed-dose ICS–LABA products with the primary outcome of life-threatening asthma exacerbation or death. The results will not be ...

Formoterol is a long-acting beta-agonist (LABA) bronchodilator, which provides long-term asthma management rather than quick symptom relief. However, the idea behind SMART therapy is that ...

The inhaler is not reusable. LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in rapidly deteriorating or potentially life-threatening ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...